Review

Discovering biomarkers in bladder cancer by metabolomics

Wen-Tao Zhang

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Anhui Medical University Shanghai Clinical College, PR China

Search for more papers by this author

Zi-Wei Zhang

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Search for more papers by this author

Ya-Dong Guo

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Search for more papers by this author

Long-Sheng Wang

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Search for more papers by this author

Shi-Yu Mao

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Search for more papers by this author

Jun-Feng Zhang

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Search for more papers by this author

Meng-Nan Liu

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Search for more papers by this author

Xu-Dong Yao

*Author for correspondence:

E-mail Address: yaoxudong1967@163.com

Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, PR China

Anhui Medical University Shanghai Clinical College, PR China

Search for more papers by this author

Published Online:3 Dec 2018https://doi.org/10.2217/bmm-2018-0229

View article

Abstract

It has become increasingly clear that the development of cancer, a multifactorial disease, cannot be explained by a single molecule or gene mutation. As a new discipline, metabolomics focuses on the body's metabolite changes, and attempts to find differences to explain the development of cancer; it has proven to be effective and credible. Metabolic studies of bladder cancer (BCa) lag behind those of other tumors. This review systematically outlines the specific process of metabolomics and the use of metabolomics in BCa studies in recent years. We have reviewed the in vitro cell line, bladder tumor tissue and biofluid (urine, plasma and serum) studies used in metabolomics analyses of BCa. The advantages and drawbacks of the use of different samples were compared. Based on the available studies, we have further described the aberrant metabolic pathways of BCa and have suggested some metabolites that may be potential biomarkers for BCa detection.

Keywords:

References

1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 66(1), 7–30 (2016).Crossref, Medline, Google Scholar
2 Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA 306(7), 737–745 (2011).Crossref, Medline, CAS, Google Scholar
3 Alfred Witjes J, Lebret T, Comperat EM et al. Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. 71(3), 462–475 (2017).Crossref, Medline, CAS, Google Scholar
4 Burger M, Catto JW, Dalbagni G et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63(2), 234–241 (2013).Crossref, Medline, Google Scholar
5 Kamat AM, Hegarty PK, Gee JR et al. ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur. Urol. 63(1), 4–15 (2013).Crossref, Medline, Google Scholar
6 Cantor GH, Beckonert O, Bollard ME et al. Integrated histopathological and urinary metabonomic investigation of the pathogenesis of microcystin-LR toxicosis. Vet. Pathol. 50(1), 159–171 (2013).Crossref, Medline, CAS, Google Scholar
7 Newgard CB. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 25(1), 43–56 (2016).Crossref, Medline, Google Scholar
8 Rodrigues D, Jerónimo C, Henrique R et al. Biomarkers in bladder cancer: a metabolomic approach using in vitro and ex vivo model systems. Int. J. Cancer 139(2), 256–268 (2016).Crossref, Medline, CAS, Google Scholar
9 Shi H, Li X, Zhang Q, Yang H, Zhang X. Discovery of urine biomarkers for bladder cancer via global metabolomics. Biomarkers 21(7), 578–588 (2016).Crossref, Medline, CAS, Google Scholar
10 Devaux PG, Horning MG, Hill RM, Horning EC. O-benzyloximes: derivatives for the study of ketosteroids by gas chromatography. Application to urinary steroids of the newborn human. Anal. Biochem. 41(1), 70–82 (1971).Crossref, Medline, CAS, Google Scholar
11 Kitano H. Systems biology: a brief overview. Science 295(5560), 1662–1664 (2002).Crossref, Medline, CAS, Google Scholar
12 Nicholson J, Wilson I. Opinion: understanding global systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug. Discov. 2(8), 668–676 (2003).Crossref, Medline, CAS, Google Scholar
13 Bansal N, Gupta A, Sankhwar SN. Proteometabolomics of bladder cancer: current and future prospects. Cancer Biomark. 15(4), 339–348 (2015).Crossref, Medline, Google Scholar
14 German JB, Bauman DE, Burrin DG et al. Metabolomics in the opening decade of the 21st century: building the roads to individualized health. J. Nutr. 134(10), 2729–2732 (2004).Crossref, Medline, CAS, Google Scholar
15 Lu W, Bennett BD, Rabinowitz JD. Analytical strategies for LC–MS-based targeted metabolomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871(2), 236 (2008).Crossref, Medline, CAS, Google Scholar
16 Field D, Sansone SA. A special issue on data standards. OMICS 10(2), 84–93 (2006).Crossref, CAS, Google Scholar
17 Johnson C, Ivanisevic J, Siuzdak G. Metabolomics: beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol. 17(7), 451–459 (2016).Crossref, Medline, CAS, Google Scholar
18 Chen S, Kong H, Lu X et al. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry. Anal. Chem. 85(17), 8326–8333 (2013).Crossref, Medline, CAS, Google Scholar
19 Luo P, Yin P, Hua R et al. A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma. Hepatology 67(2), 662–675 (2018).Crossref, Medline, CAS, Google Scholar
20 Zhou Y, Song R, Zhang Z et al. The development of plasma pseudotargeted GC–MS metabolic profiling and its application in bladder cancer. Anal. Bioanal. Chem. 408(24), 6741–6749 (2016).Crossref, Medline, CAS, Google Scholar
21 Zhou Y, Song R, Ma C et al. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC–MS metabolomics method. Oncotarget 8(13), 20719–20728 (2017).Crossref, Medline, Google Scholar
22 Aboud OA, Weiss RH. New opportunities from the cancer metabolome. Clin. Chem. 59(1), 138–146 (2013).Crossref, Medline, Google Scholar
23 Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst 137(2), 293 (2012).Crossref, Medline, CAS, Google Scholar
24 Roux A, Lison D, Junot C, Heilier JF. Applications of liquid chromatography coupled to mass spectrometry-based metabolomics in clinical chemistry and toxicology: a review. Clin. Biochem. 44(1), 119–135 (2011).Crossref, Medline, CAS, Google Scholar
25 Qiu Y, Su M, Liu Y et al. Application of ethyl chloroformate derivatization for gas chromatography–mass spectrometry based metabonomic profiling. Analytica. Chimica. Acta 583(2), 277–283 (2007).Crossref, Medline, CAS, Google Scholar
26 Zhou B, Xiao JF, Tuli L, Ressom HW. LC–MS-based metabolomics. Mol. Biosyst. 8(2), 470 (2012).Crossref, Medline, CAS, Google Scholar
27 Gika HG, Theodoridis GA, Plumb RS, Wilson ID. Current practice of liquid chromatography–mass spectrometry in metabolomics and metabonomics. J. Pharmaceut. Biomed. 87(1434), 12–25 (2014).Crossref, Medline, CAS, Google Scholar
28 Doerfler H, Lyon D, Nägele T et al. Granger causality in integrated GC–MS and LC–MS metabolomics data reveals the interface of primary and secondary metabolism. Metabolomics 9(3), 1–11 (2013).Crossref, Google Scholar
29 Sahu D, Lotan Y, Wittmann B, Neri B, Hansel D. Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Med. 6(9), 2106–2120 (2017).Crossref, Medline, CAS, Google Scholar
30 Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J. Proteome Res. 6(2), 469–479 (2007).Crossref, Medline, CAS, Google Scholar
31 Kettaneh N, Berglund A, Wold S. PCA and PLS with very large data sets. Comput. Stat. Data Anal. 48(1), 69–85 (2005).Crossref, Google Scholar
32 Goodacre R, Broadhurst D, Smilde AK et al. Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics 3(3), 231–241 (2007).Crossref, CAS, Google Scholar
33 Berg RaVD, Hoefsloot HC, Westerhuis JA, Smilde AK, Werf MJVD. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics 7(1), 142 (2006).Crossref, Medline, Google Scholar
34 Wagner S, Scholz K, Sieber M, Kellert M, Voelkel W. Tools in metabonomics: an integrated validation approach for LC–MS metabolic profiling of mercapturic acids in human urine. Anal. Chem. 79(7), 2918–2926 (2007).Crossref, Medline, CAS, Google Scholar
35 Lutz U, Lutz RW, Lutz WK. Metabolic profiling of glucuronides in human urine by LC–MS/MS and partial least-squares discriminant analysis for classification and prediction of gender. Anal. Chem. 78(13), 4564–4571 (2006).Crossref, Medline, CAS, Google Scholar
36 Rantalainen M. Combining metabonomics and other -omics data. Methods Mol. Biol. 1277, 147–159 (2015).Crossref, Medline, CAS, Google Scholar
37 Berger B, Peng J, Singh M. Computational solutions for omics data. Nat. Rev. Genet. 14(5), 333–346 (2013).Crossref, Medline, CAS, Google Scholar
38 Tan G, Wang H, Yuan J et al. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer. Sci. Rep. 7, 46176 (2017).Crossref, Medline, CAS, Google Scholar
39 Kim WT, Yun SJ, Yan C et al. Metabolic pathway signatures associated with urinary metabolite biomarkers differentiate bladder cancer patients from healthy controls. Yonsei. Med. J. 57(4), 865–871 (2016).Crossref, Medline, CAS, Google Scholar
40 Conde VR, Oliveira PE, Nunes AR et al. The progression from a lower to a higher invasive stage of bladder cancer is associated with severe alterations in glucose and pyruvate metabolism. Exp. Cell Res. 335(1), 91–98 (2015).Crossref, Medline, CAS, Google Scholar
41 Wittmann BM, Stirdivant SM, Mitchell MW et al. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS ONE 9(12), 115870 (2014).Crossref, Google Scholar
42 Shen C, Sun ZY, Chen DY et al. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. OMICS 19(1), 1–11 (2015).Crossref, Medline, CAS, Google Scholar
43 Alberice JV, Amaral AF, Armitage EG et al. Searching for urine biomarkers of bladder cancer recurrence using a liquid chromatography–mass spectrometry and capillary electrophoresis–mass spectrometry metabolomics approach. J. Chromatogr. A. 1318, 163–170 (2013).Crossref, Medline, CAS, Google Scholar
44 Dettmer K, Vogl FC, Ritter AP et al. Distinct metabolic differences between various human cancer and primary cells. Electrophoresis 34(19), 2836–2847 (2013).Medline, CAS, Google Scholar
45 Tripathi P, Somashekar BS, Ponnusamy M et al. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. J. Proteome Res. 12(7), 3519–3528 (2013).Crossref, Medline, CAS, Google Scholar
46 Pasikanti KK, Esuvaranathan K, Hong YJ et al. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. J. Proteome Res. 12(9), 3865–3873 (2013).Crossref, Medline, CAS, Google Scholar
47 Huang Z, Lin L, Gao Y et al. Bladder cancer determination via two urinary metabolites: a biomarker pattern approach. Mol. Cell. Proteomics 10(10), M111 007922 (2011).Crossref, Google Scholar
48 Putluri N, Shojaie A, Vasu VT et al. Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 71(24), 7376 (2011).Crossref, Medline, CAS, Google Scholar
49 Kim W-J, Kim E-J, Kim S-K et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer 9(1), 3 (2010).Crossref, Medline, Google Scholar
50 Bansal N, Gupta A, Mitash N et al. Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. J. Proteome Res. 12(12), 5839–5850 (2013).Crossref, Medline, CAS, Google Scholar
51 Issaq HJ, Nativ O, Waybright T et al. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J. Urol. 179(6), 2422–2426 (2008).Crossref, Medline, CAS, Google Scholar
52 Hyndman ME, Mullins JK, Bivalacqua TJ. Metabolomics and bladder cancer. Urologic Oncology: Seminars and Original Investigations 29(5), 558–561 (2011).Crossref, Medline, CAS, Google Scholar
53 Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ, Park S. Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget 5(6), 1635–1645 (2014).Crossref, Medline, Google Scholar
54 Warburg O. On the origin of cancer cells. Science 123(3191), 309–314 (1956).Crossref, Medline, CAS, Google Scholar
55 Pasikanti KK, Esuvaranathan K, Ho PC et al. Noninvasive urinary metabonomic diagnosis of human bladder cancer. J. Proteome Res. 9(6), 2988–2995 (2010).Crossref, Medline, CAS, Google Scholar
56 Rhodes DR, Kalyanasundaram S, Tomlins SA et al. Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9(5), 443–454 (2007).Crossref, Medline, CAS, Google Scholar
57 Loras A, Trassierra M, Sanjuan-Herráez D et al. Bladder cancer recurrence surveillance by urine metabolomics analysis. Sci. Rep. 8(1), 9172 (2018).Crossref, Medline, CAS, Google Scholar
58 Jobu K, Sun C, Yoshioka S et al. Metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer. Biol. Pharm. Bull. 35(4), 639–642 (2012).Crossref, Medline, CAS, Google Scholar
59 Wood DP. Re: metabolomics study on the biochemical profiles of odor elements in urine of human with bladder cancer. J. Urol. 189(4), 1288 (2013).Crossref, Medline, CAS, Google Scholar
60 Kim JW, Lee G, Moon SM et al. Metabolomic screening and star pattern recognition by urinary amino acid profile analysis from bladder cancer patients. Metabolomics 6(2), 202–206 (2010).Crossref, CAS, Google Scholar
61 Walsh MC, Brennan L, Malthouse JPG, Roche HM, Gibney MJ. Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am. J. Clin. Nutr. 84(3), 531–539 (2006).Crossref, Medline, CAS, Google Scholar
62 Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature 489(7415), 242–249 (2012).Crossref, Medline, CAS, Google Scholar
63 Cuperlovic-Culf M, Barnett DA, Culf AS, Chute I. Cell culture metabolomics: applications and future directions. Drug Discov. Today 15(15-16), 610–621 (2010).Crossref, Medline, CAS, Google Scholar
64 Brochez L, Chevolet I, Kruse V. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. Eur. J. Cancer 76, 167–182 (2017).Crossref, Medline, CAS, Google Scholar
65 Ghasemzadeh A, Bivalacqua TJ, Hahn NM, Drake CG. New strategies in bladder cancer: a second coming for immunotherapy. Clin. Cancer Res. 22(4), 793–801 (2016).Crossref, Medline, CAS, Google Scholar
66 Theate I, Van Baren N, Pilotte L et al. Extensive profiling of the expression of the indoleamine 2,3-dioxygenase 1 protein in normal and tumoral human tissues. Cancer Immunol. Res. 3(2), 161–172 (2015).Crossref, Medline, CAS, Google Scholar
67 Van Baren N, Van Den Eynde BJ. Tumoral immune resistance mediated by enzymes that degrade tryptophan. Cancer Immunol. Res. 3(9), 978–985 (2015).Crossref, Medline, CAS, Google Scholar
68 Hudolin T, Mengus C, Coulot J, Kastelan Z, El-Saleh A, Spagnoli GC. Expression of indoleamine 2, 3-dioxygenase gene is a feature of poorly differentiated non-muscle-invasive urothelial cell bladder carcinomas. Anticancer Res. 37(3), 1375–1380 (2017).Crossref, Medline, CAS, Google Scholar
69 Yang CG, Zhou YC, Zhang LJ, Jin CG, Li M, Ye LJ. Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma. Int. J. Clin. Exp. Pathol. 8(2), 1768–1775 (2015).Medline, CAS, Google Scholar
70 Gangadhar TC, Hamid O, Smith DC et al. Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated Phase 1 results from ECHO-202/KEYNOTE-037. Ann. Oncol. 27(Suppl. 6), (2016).Google Scholar
71 Rizvi NA, Hellmann MD, Snyder A et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small-cell lung cancer. Science 348(6230), 124–128 (2015).Crossref, Medline, CAS, Google Scholar
72 Pertovaara M, Heliovaara M, Raitala A, Oja SS, Knekt P, Hurme M. The activity of the immunoregulatory enzyme indoleamine 2,3-dioxygenase is decreased in smokers. Clin. Exp. Immunol. 145(3), 469–473 (2006).Crossref, Medline, CAS, Google Scholar
73 Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67(3), 519–530 (2015).Crossref, Medline, Google Scholar
74 Godlewski J, Nowicki MO, Bronisz A et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37(5), 620–632 (2010).Crossref, Medline, CAS, Google Scholar
75 Yang X, Cheng Y, Li P et al. A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36(1), 383 (2015).Crossref, Medline, CAS, Google Scholar
76 Schlaepfer IR, Rider L, Rodrigues LU et al. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol. Cancer Ther. 13(10), 2361–2371 (2014).Crossref, Medline, CAS, Google Scholar
77 Patsoukis N, Bardhan K, Chatterjee P et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation.Nat. Commun. 6, 6692 (2015).Crossref, Medline, CAS, Google Scholar
78 Zhao F, Xiao C, Evans KS et al. Paracrine wnt5a-β-catenin signaling triggers a metabolic program that drives dendritic cell tolerization. Immunity 48(1), 147–160 (2018).Crossref, Medline, CAS, Google Scholar

Vol. 12, No. 12

Metrics

Downloaded 215 times

History

Received 6 July 2018

Accepted 17 October 2018

Published online 3 December 2018

Published in print December 2018

Information

Keywords

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

PDF download